Significantly, our analysis of 620 breast cancer patients treated with anthracyclines or taxanes showed that patients with primary tumors expressing high levels of IL-6R or CCR2 are significantly less likely to respond to either chemotherapy compared with low receptor expression. This evidence concerns the gene IL6R and breast carcinoma.